GnRH Agonists Alter Body Composition After Long-Term Exposure

GnRH agonists are a common non-surgical treatment for prostate cancer, as well as a male contraception method. The GnRH agonists effectively shut down the reproductive axis in many male mammals. In 2007, approximately 600,000 men used GnRH therapy for prostate cancer treatment. GnRH therapy (ADT) is accompanied with various side effects, including hot flashes, and most recently an increased risk of cardiovascular disease. The risk of cardiovascular disease does not appear to be androgen dependent, and prompted an FDA warning in October of 2010. Previous research indicates an ADT promoted metabolic change in men. This study investigated the long-term effects of ADT in the male rat to investigate comparable metabolic changes, through a constant release deslorelin. Preliminary data revealed a significant effect of ADT on weight gain. Following cessation, weight is rapidly restored. The mechanism remains undetermined, however evidence suggests GnRH may directly affect myocytes.